Posted by Michael Wonder on 22 Dec 2024
BioGenCell receives FDA fast track designation with expanded access for BGC101
19 December 2024 - BioGenCell announced that the US FDA has granted fast track designation to its lead candidate, BGC101, for treating severe critical limb threatening ischaemia.
BGC101 aims to prevent amputations, hinder disease progression and relieve pain for severe critical limb threatening ischaemia patients - offering hope to no-option patients.
